Fortis Healthcare Ltd. · NSE:FORTIS
Fortis Healthcare — Q1 FY2020 Earnings Presentation
66 slides from Fortis Healthcare's earnings presentation, Aug 6, 2019
Slide 1: Outcome of the Board Meeting
Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel : 0124 492 1033 Fax : 0124 492 1041 Emergency : 105010 Email : secretarial@fortishealthcare.com Website : www.fortishealthcare.com FHL/SEC / 2019-20 August 6, 2019 The
Slide 2: Limited review report on standalone results
BSR & Co. LLP Chartered Accountants Building No. 10, 8th Floor, Tower-B Telephone: +91 124 719 1000 DLF Cyber City, Phase - I! Fax: +91 124 235 8613 Gurugram - 122 002, India Limited review report on the Statement of Unaudited Standalone financial Results of Fortis Healthcare Limited pursuant to the
Slide 3: Limited review report (continued)
BSR & Co. LLP (ii) including completeness of related party transactions which relate to or which originated prior to loss of control of erstwhile promoters/directors in the year ended 31 March 2018. Further, as explained in Note 11 and 12 of the Statement, various regulatory authorities including Se
Slide 4: Statement of Unaudited Standalone Results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PLC045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (Rupees in lacs) Particulars Standalone — Quarter ended Year ended June 30, March 31, June 30, March 3
Slide 5: Statement of Unaudited Standalone Results (continued)
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (Rupees in lacs) Particulars Standalone ] Quarter ended Year ended June 30, March 31, June 30, March 31
Slide 6: Notes to standalone results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 4. Exceptional items included in the above standalone financial results include: (Rupees in lacs) Quart
Slide 7: Notes to standalone results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 itself to be representative of the Party and is seeking substitution of its name in place of Assignee a
Slide 8: Notes to standalone results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 acquiring control over the Company. Consequently, the Company has become a subsidiary of Northern TK Ve
Slide 9: Notes to standalone results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 iii. vi. vii. of the relationship. In this regard, reference was made to Indian accounting Standards de
Slide 10: Notes to standalone results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (f) With respect to the other matters identified in the Investigation Report, the Board initiated speci
Slide 11: Notes to standalone results
STATE! FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 MENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 12. 13. Securities and Exchange Board of India Act 1992, for the recovery of the amounts owed by the
Slide 12: Notes to standalone results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 14 15. 16. qf; 18. 19. 20. Financial Results with respect to these claims. Subsequently, Company has fi
Slide 13: Notes to standalone results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 the results of the various investigations are known. With regard to other comments all identified adjus
Slide 14: Limited review report on consolidated results
BSR & Co. LLP Chartered Accountants Building No. 10, 8th Floor, Tower-B Telephone: +91 124 719 1000 DLF Cyber City, Phase - 1! Fax: +914 124 235 8613 Gurugram - 122 002, India Limited review report on the Statement of Unaudited Consolidated financial Results of Fortis Healthcare Limited pursuant to
Slide 15: Limited review report (list of entities)
BSR & Co. LLP XXV. Xxvi. XXVii. xxvili. xxix. XXX. XXxxi. Xxxii. Xxxiii. XXXIV. XXXV. XXXVi. XXxVii. SRL Limited SRL Diagnostics Private Limited SRF Reach Limited SRL Diagnostics FZ-LLC SRL Diagnostics Middle East LLC Fortis Hospotel Limited Escort Heart and Super Speciality Hospital Limited Interna
Slide 16: Limited review report (continued)
BSR & Co. LLP Consequently, the need for additional procedures/ enquiries, if any, and an overall assessment of the impact of the investigations on the financial results is yet to be concluded. Also, as explained in Note 11 of the Statement, a Civil Suit claiming Rs. 25,344 lacs was filed by a third
Slide 17: Limited review report (continued)
10. BSR & Co. LLP Based on the advice given by external legal counsel, the management believes that outflow in the above litigations is not likely and accordingly no provision/adjustment has been considered necessary with respect to the above matters in the Statement. Our conclusion is not modified
Slide 18: Statement of Unaudited Consolidated Results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PLC045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (Rupees in lacs) Particulars Consolidated Quarter ended Year ended June 30, March 31, 2019 | June 30
Slide 19: Statement of Unaudited Consolidated Results (continued)
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (Rupees in lacs) Particulars Consolidated Quarter ended Year ended June 30, March 31, 2019 | June 30,
Slide 20: Consolidated results notes and segment reporting
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 2. The predecessor auditor had issued a qualified opinion on the unaudited consolidated financial res
Slide 21: Segment liabilities and exceptional items
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (Rupees in lacs) S.No Particulars Quarter Ended Year Ended June 30, 2019 March 31, 2019 June 30, 2018
Slide 22: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 6. Fortis Hospitals Limited (FHsL), a wholly owned subsidiary of the Company, had placed secured Shor
Slide 23: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 for Rupees 304 lacs incurred pertaining to the office space. Vide order dated 20th February, 2019 Hon
Slide 24: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 Income Tax Appellate Tribunal (ITAT) and during the current quarter ended June 30, 2019, ITAT decided
Slide 25: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 The Company has filed written statement denying all allegations made against it and prayed for dismis
Slide 26: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 15. 16. 1%; sale/deconsolidation aggregating to Rupees 307 lacs has been shown as an exceptional item
Slide 27: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase - VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (b) (c) (d) Committee of the Company in its meeting on February 13, 2018 decided to carry out an inde
Slide 28: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 note 6). Whilst the matter was included as part of the terms of reference of the investigation, the m
Slide 29: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (9) committees and their functional role. The Company's Board of Directors have also initiated _ addi
Slide 30: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — Vill, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 and FHsL may take necessary steps to comply with SEBI’s direction. Company is taking steps for filing
Slide 31: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 20. 21. 22. 23. 24. agreement. The Company has replied to the same through its legal counsel denying
Slide 32: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 25. Effective April 1, 2019, the Group adopted Ind AS 116 "Leases" using the modified retrospective m
Slide 33: Notes to consolidated results
FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PL045933 Fortis Hospital, Sector 62 Phase — VIII, Mohali - 160062 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (c) With regard to the comments of the statutory auditors in paragraph 6 (iii) of Limited Review Repo
Slide 34: Fortis Healthcare announces Q1 FY20 Consolidated Financial Results
Press Release August 6, 2019 Fortis Healthcare announces Q1 FY20 Consolidated Financial Results Revenues grow 9.2% to INR 1138 Crs Operating EBITDA increases 9.4x to INR 142.3 Crs (12.5% margin versus 1.4%) Profit After Tax* at INR 67.8 Crs versus a loss of INR 70.9 Crs in Q1 FY 19 Hospital business
Slide 35: Press Release: Key Financial Highlights
Press Release August 6, 2019 o Initiatives to improve manpower productivity in both medical and non-medical areas underway. o Focus continues on improving cost efficiencies and further rationalization for improved Lab optimization and higher productivity in the diagnostics business * PAT after Minor
Slide 36: Press Release: Management commentary
Press Release August 6, 2019 accelerate the Company’s growth momentum and at the same time ensure further strengthening of its systems and processes.” Commenting on the results, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “Our Q1 results signify the momentum that we continue to se
Slide 37: Fortis Healthcare Limited – Q1 FY2020
Fortis Healthcare Limited Earnings Presentation – Q1 FY2020 “ Saving and Enriching Lives” August 6, 2019
Slide 38: Disclaimer
Disclaimer This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been pr
Slide 39: Agenda
Agenda 1. Key Highlights 2. Key Financial Summary – Q1FY20 3. Executive Results Summary 4. Performance Review – Hospitals Business 5. Performance Review – Diagnostics Business 6. Appendix
Slide 40: 1. Key Highlights
1. Key Highlights 42 Fortis
Slide 41: Key Highlights – Q1 FY20
Key Highlights – Q1 FY20 – Hospital business EBITDA increases 120% to INR 92 Cr i.e. 10.1% margin; Significant improvement in Diagnostics business EBITDA at INR 53.7 Cr, 23.9% margins versus 18.7% profitability – Consolidated Operating earnings (PBT*) for the quarter stood at INR 20.4 Cr versus a lo
Slide 42: 2. Key Financial Summary – Q1 FY20
2. Key Financial Summary – Q1 FY20 6
Slide 43: Financial Highlights - Q1 FY20
Financial Highlights - Q1 FY20 • Consolidated Revenues at INR 1,138.3 Cr, up 9.2% ➢ Hospital business revenues at INR 913 Cr, up 11.3% (highest growth in last 11 quarters) ➢ Diagnostics business net revenues at INR 225 Cr, up 4.0% • Operating margins (EBITDAC*) at 12.5% versus 7.7% in Q1 FY20 ➢ Hosp
Slide 44: Quarterly Revenues and Margins - Q1 FY20
Quarterly Revenues and Margins - Q1 FY20 Consolidated Business Revenue EBITDAC INR Cr 1,400 250 1,184 1,200 1,140 1,103 1,138 1,042 200 1,000 182 800 150 142 142 137 15.4% 600 12.5% 100 12.5% 12.4% 400 80 13.7%* 12.8%* 50 200 7.7% - - Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 • Consistent improvement in Op
Slide 45: 3. Executive Results Summary
3. Executive Results Summary 9
Slide 46: Executive Summary – Q1 FY20
Executive Summary – Q1 FY20 Consolidated Financials QoQ Particulars (INR Cr) Q1FY19 Q4FY19 Q1FY20 % Change Revenue 1,042.0 1,184.1 1,138.3 9.2% Operating EBITDAC* 80.4 182.2 142.3 76.9% Operating EBITDAC margin 7.7% 15.4% 12.5% Operating EBITDA 15.1 167.1 142.3 Operating EBITDA margin 1.4% 14.1% 12.
Slide 47: Balance Sheet – June 30, 2019
Balance Sheet – June 30, 2019 Balance Sheet (INR Cr) June 30, 2018 March 31, 2019 June 30, 2019 Shareholder’s Equity 5,299 7,175 7,191 Debt 1,657 2,009 1,388 Lease Liabilities (Ind AS 116)* - - 196 Total Capital Employed 6,955 9,184 8,775 Net Fixed Assets (includes CWIP) 3,128 5,206 5,351 Goodwill 2
Slide 48: Business Summary Highlights
Business Summary Highlights INR Crore Hospitals Business Revenue EBITDAC • Both Hospitals and Diagnostics business 1000 900 889 919 913 120 820 continues to witness traction in operations 800 107 100 100 92 • Hospital business performance witnessed 88 80 600 11.2% 11.7% steady improvement over Q1FY1
Slide 49: 4. Performance Review – Hospitals Business
4. Performance Review – Hospitals Business 13
Slide 50: India Hospital Business – Q1 FY20
India Hospital Business – Q1 FY20 Q1FY19 Q4FY19 Q1FY20** QoQ • International patient revenue Particulars % Change (INR Cr.) (INR Cr.) (INR Cr.) at INR 92 Cr, + 2% growth over Operating Revenue 819.9 918.5 913.0 11.3% corr. quarter • Key Hospitals revenue growth Operating EBITDAC* 41.8 107.2 92.1 120
Slide 51: Key Performance Metrics – Hospitals Business
Key Performance Metrics – Hospitals Business Occupancy (%) ARPOB (INR Cr per annum) ALOS (Days) 1.57 69% 68% 68% 66% 3.42 3.42 3.39 1.53 1.53 3.34 62% 1.51 1.49 3.17 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 Q3FY19 Q1FY19 Q2FY19 Q4FY19 Q1FY20 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 15
Slide 52: Specialty Mix & Payor Mix – Q1 FY20
Specialty Mix & Payor Mix – Q1 FY20 Specialty Mix Payor Mix Other Operating ECHS, 5.6% CGHS, 2.7% Revenue, International , 2.4% Govt & PSUs, 9.7% 8.1% Pvt Corps, OPD & 1.5% Cardiac, 22% Others, 17% IPD & Others, Ortho, 9% 16% TPAs, 28.0% Cash:Domestic, Renal , 8% 41.3% Gynecology, 4% Pulmonology, Ne
Slide 53: Key Initiatives – Q1 FY20
Key Initiatives – Q1 FY20 Fortis Hospital, Anandapur, Kolkata, conducted a cardiac surgical camp at Asia Royal Hospital, Yangon, Myanmar. Under the initiative, a team of doctors from Fortis Anandapur travelled to Yangon and conducted three cardiac surgeries. Fortis Hospital, Kalyan, launched a d
Slide 54: Advanced Technology Treatments and Ongoing Expansions
Advanced Technology Treatments and Ongoing Expansions ➢ Robotic Program at Forti Mulund, Mumbai ➢ Oncology Block at Fortis BG Road, Bengaluru ➢ Multi-specialty facility at Arcot Road, Chennai ➢ Liver Transplant facility at Fortis Noida, NCR 18
Slide 55: Robotic Program launched at Fortis Mulund, Mumbai
Robotic Program launched at Fortis Mulund, Mumbai 19
Slide 56: Fortis BG Road, Bengaluru – Oncology Block Commissioned
Fortis BG Road, Bengaluru – Oncology Block Commissioned Commissioned Basement + 3 floors – Total capacity ~200 beds Lower basement Linac Corridor Ground Floor Waiting Area Ground Floor Chemo Area First Floor Consultation Area First Floor Endoscopy Area Patient Relative Waiting Area 20
Slide 57: Fortis Arcot Road, Chennai – To be Commissioned Shortly
Fortis Arcot Road, Chennai – To be Commissioned Shortly ~200 bed multi-speciality facility 21
Slide 58: Clinical Excellence and Awards & Accolades – Q1 FY20
Clinical Excellence and Awards & Accolades – Q1 FY20 A team of Doctors at Fortis Escorts, New Delhi performed the rare, non-surgical catheter based Fortis Hospital, Noida, has received the Ethics Transcatheter Mitral Valve Replacement (TMVR) Committee accreditation from National Accreditation proced
Slide 59: 5. Performance Review – Diagnostics Business
5. Performance Review – Diagnostics Business 23
Slide 60: Diagnostics Business – Q1 FY20
Diagnostics Business – Q1 FY20 Gross Revenue EBITDA Margin ➢ Gross Operating revenue at INR 258 Cr, +4.2% (like for INR Cr 300 258 30.0% like growth ~6%); Growth driven by new direct clients 248 251 as well as the hospitals segment 200 20.0% 19.5% 20.8% ➢ Operating EBITDA margin basis gross revenue
Slide 61: Key Performance Metrics
Key Performance Metrics Number of Tests and Average Realizations* Direct Cost per test No of tests (mn) Average realisation per Test (INR) Direct Cost per test (INR) 500 10 7.98 7.8 83.8 82.9 400 8 81.3 81.9 79.7 7.36 7.32 7.4 335 334 331 336 300 329 6 200 4 100 2 - 0 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19
Slide 62: Revenue Mix
Revenue Mix Geographic Mix Customer Mix International 4% International, Clinical Trial, Wellness, 3% 4% 0% West North Q1FY2020 Q1FY2020 25% 33% Direct Client, Walk-in, 36% 18% South Hospitals, 21% 17% East 21% CC, 17% International Clinical International, Wellness, 3% , 2% Trial, 0% 2% Direct Client
Slide 63: 6. Appendix
6. Appendix , 42 Fortis
Slide 64: Group Consolidated P&L – Q1 FY20
Group Consolidated P&L – Q1 FY20 Q1FY19 Q4FY19 Q1FY20^^ Particulars QoQ % Change (INR Cr.) (INR Cr.) (INR Cr.) Operating Revenue 1,042.0 1,184.1 1,138.3 9.2% Operating EBITDAC* 80.4 182.2 142.3 76.9% Operating EBITDAC margin 7.7% 15.4% 12.5% Net BT Costs 65.3 15.1 - Operating EBITDA 15.1 167.1 142.3
Slide 65: India Consolidated P&L – Q1 FY20
India Consolidated P&L – Q1 FY20 Q1FY19 Q4FY19 Q1FY20^^ Particulars QoQ % Change (INR Cr.) (INR Cr.) (INR Cr.) Operating Revenue 1,036.3 1,135.3 1,138.1 9.8% Operating EBITDAC* 82.4 156.2 145.9 77.0% Operating EBITDAC margin 7.9% 13.8% 12.8% Net BT Costs 65.3 15.1 - -100.0% Operating EBITDA 17.0 141
Slide 66: Thank You
For further details please contact: Anurag Kalra / Gaurav Chugh Investor Relations +91-9810109253 / 9958588900 Fortis Healthcare Limited Thank You 30